Ligand Pharmaceuticals (LGND) — who pays, who partners, and how revenue is sourced

Ligand monetizes a portfolio of royalty assets, long‑term material supply and licensing/milestone agreements. The company earns recurring cash through royalties on partnered drugs, sales of its Captisol excipient, and contract revenue from license fees and milestones, while selectively financing royalties and investing in partner programs to accelerate near‑term cash flows. For investors, the relevant lens is concentration and contract tenure: a handful of partners drive most royalties, Captisol supplies are contractual and global, and milestone flows are episodic but material. Learn more at https://nullexposure.com/ for full coverage and sourcing.

What investors should take away about Ligand’s operating model

Ligand operates as a hybrid seller of a platform material (Captisol) and owner/financier of royalty streams and license rights. That positioning produces three operational characteristics that matter to underwriters and portfolio managers:

• Contracting posture: Ligand executes long‑term supply and license agreements that convert future royalties and material sales into predictable cash; filings disclose multi‑year arrangements.
• Concentration and criticality: A relatively small set of marketed drugs (Kyprolis, Filspari, Qarziba, etc.) account for a significant portion of royalty revenue, exposing Ligand to partner sales execution and pricing.
• Global footprint and maturity: Royalty contracts generate payments across the U.S., Europe and other regions, while Captisol supply is managed under commercial license and multi‑year supply agreements.

The company’s constraints reinforce this profile: filings state a 10‑year supply agreement supplying Captisol to Gilead, royalties are sourced globally, and Ligand presents itself primarily as a seller with Captisol as a core product (Captisol sales growth cited in FY2024 results).

A complete, plain‑English map of every named relationship in the record

Below are one‑ to two‑sentence notes on each relationship listed in the results, with the source indicated for investor diligence.

• Acrotech Biopharma — Ligand’s FY2024 10‑K notes that royalty receipts include sales of Evomela sold by Acrotech, linking that product to a portion of Ligand’s royalty revenue (FY2024 10‑K).
• Spectrum Pharmaceuticals, Inc. — Ligand’s FY2024 10‑K references a license agreement originally dated March 8, 2013 between CyDex and Spectrum, indicating legacy contractual ties noted in the filing (FY2024 10‑K).
• Alvogen/Adalvo — Ligand’s FY2024 10‑K identifies royalties tied to Teriparatide produced by Alvogen/Adalvo as part of its royalty revenue base (FY2024 10‑K).
• GenScript ProBio — A 2021 PR Newswire release documents a global OmniAb licensing agreement with GenScript ProBio to commercialize Ligand’s OmniAb platform in China, expanding OmniAb’s commercial footprint (PR Newswire, 2021).
• Jazz (JAZZ) — Ligand’s FY2024 10‑K calls out royalties on Rylaze sold by Jazz as a component of its royalty portfolio (FY2024 10‑K).
• Gilead (GILD) — Analysts noted that Ligand expects increased Captisol sales to Gilead as Gilead rebuilds Veklury inventories, making Gilead a material Captisol demand source (Zacks industry commentary, 2024).
• Merck (MRK) — Market commentary identifies Merck’s products (Ohtuvayre, Capvaxive) as expected royalty drivers for Ligand, reflecting ongoing commercialization payments (Zacks, 2024).
• Verona Pharma (VRNA) — A Pharmaphorum report notes Ligand earned an FDA‑approval milestone on Verona’s Ohtuvayre and expects launch payments and single‑digit royalties (Pharmaphorum, 2024).
• Verona (duplicate coverage) — Analyst pieces reiterate Verona’s Ohtuvayre as a near‑term royalty contributor in Ligand’s 2025 outlook (Zacks, 2024).
• Viking Therapeutics (VKTX) — Zacks reported contract revenue expectations of $10–$20 million for Ligand in connection with Viking’s NASH program, with $10 million specifically attributed to that program (Zacks, 2024).
• Pelthos Therapeutics (PTHS) — QuiverQuant reported Ligand earned a $5 million milestone payment from Pelthos after the commercial launch of ZELSUVMI, demonstrating milestone cash flow on new launches (QuiverQuant, FY2025 report).
• Bristol Myers Squibb (BMY) — OncologyPipeline coverage lists a partnership involving an Agenus/BMS bispecific program that carries a Ligand interest, signaling participation in upstream royalty upside (OncologyPipeline, 2024).
• BeiGene (BGNE) — Pharmaphorum notes that one product is sold by Recordati globally except China, where BeiGene holds rights, with both licensees paying royalties to Ligand (Pharmaphorum, 2024).
• Incyte (INCY) — OncologyPipeline references Tuparstobart (Agenus/Incyte) programs in early‑stage trials that include royalty interests attributable to Ligand’s financing structure (OncologyPipeline, 2024).
• Jazz Pharmaceuticals (duplicate) — OncologyPipeline reiterates Rylaze as a marketed product that generates low single‑digit royalties to Ligand (OncologyPipeline, 2024).
• Recordati — Pharmaphorum and Ligand’s filings identify Qarziba sales by Recordati as a notable royalty source for Ligand (Pharmaphorum; FY2024 10‑K).
• Merck & Co (duplicate) — OncologyPipeline lists Merck programs in Ligand’s royalty mix, reaffirming Merck as a recurring partner (OncologyPipeline, 2024).
• Amgen (AMGN) — OncologyPipeline and Ligand filings show Kyprolis sales by Amgen generate a 1.5–3% royalty to Ligand, making Amgen a core royalty counterparty (OncologyPipeline; FY2024 10‑K).
• Corvus Pharmaceuticals (CRVS) — OncologyPipeline cites CPI‑444 as an asset in Corvus’s pipeline that carries a mid‑single digit to low‑teens royalty projection tied to Ligand’s interest (OncologyPipeline, 2024).
• Travere Therapeutics (TVTX) — Analysts and Ligand’s communications identify Filspari as one of Ligand’s top revenue contributors, sourced from a 9% royalty on Travere sales (Zacks; FY2024 filings).
• Travere (duplicate) — QuiverQuant lists Filspari among the key royalty drivers in Ligand’s 2026 guidance, reinforcing Travere’s revenue importance (QuiverQuant, FY2025).
• Zydus Cadila — OncologyPipeline flags marketed biosimilars (Bryxta/Zybev and Vivitra) with undisclosed royalty terms linked to Ligand’s partnered portfolio (OncologyPipeline, 2024).
• Agenus (AGEN) — OncologyPipeline reports that Agenus assigned multiple projects to Ligand to fund clinical work, illustrating Ligand’s role as a financier of development in exchange for royalty interests (OncologyPipeline, 2024).
• Gilead Sciences (duplicate PR release) — A 2021 PR Newswire release lists Gilead among the large pharma companies with which Ligand has established alliances and licenses (PR Newswire, 2021).
• Amgen (GlobeNewswire) — A 2025 press release lists Amgen among Ligand’s strategic alliance partners, reflecting repeated public acknowledgements of that relationship (GlobeNewswire, 2025).
• Baxter International (BAX) — GlobeNewswire and other releases include Baxter in Ligand’s roster of established alliance partners (GlobeNewswire, 2025).
• Gilead Sciences (GlobeNewswire duplicate) — GlobeNewswire materials reiterate Gilead as a longstanding alliance partner (GlobeNewswire, 2025).
• Merck (GlobeNewswire duplicate) — GlobeNewswire lists Merck among Ligand’s partner roster in its 2025 communications (GlobeNewswire, 2025).
• Pfizer (PFE) — GlobeNewswire and quarterly disclosures include Pfizer in Ligand’s list of strategic partners (GlobeNewswire; investor releases, 2025–2026).
• Arcellx (ACLX) — OncologyPipeline documents an early‑stage CAR‑T program (ACLX‑001) associated with Ligand’s royalty exposure for future success (OncologyPipeline, 2024).
• Gilead (OncologyPipeline) — OncologyPipeline highlights Agenus/Gilead programs where Ligand retains a percentage interest tied to clinical progress (OncologyPipeline, 2024).
• MEI Pharmaceuticals (MEIP) — OncologyPipeline lists ME‑344 as a Phase‑1 program that would generate low single‑digit royalties under Ligand’s financing arrangements (OncologyPipeline, 2024).
• Sermonix Pharmaceuticals — OncologyPipeline cites lasofoxifene as a Phase‑3 asset with projected royalties in the mid‑single digits, reflecting Ligand’s participation in late‑stage programs (OncologyPipeline, 2024).
• UroGen (URGN) — OncologyPipeline references UGN‑301 as an early program tied to Ligand’s interests, reflecting exposure to bladder cancer development milestones (OncologyPipeline, 2024).
• Xi'an Xintong — OncologyPipeline reports MB07133 as a Phase‑2 cytarabine prodrug with a stated royalty level, adding geographic and product diversity to Ligand’s portfolio (OncologyPipeline, 2024).
• GenScript Biotech Corporation (GNNSF) — A PR Newswire announcement describes a strategic OmniAb licensing agreement with GenScript Biotech and GenScript ProBio to broaden OmniAb commercialization (PR Newswire, 2021).
• Janssen (JNJ) — PR Newswire releases and Ligand statements list Janssen among the major biopharma partners that have licensed or allied with Ligand (PR Newswire, 2021).
• Jazz (QuiverQuant FY2026) — Ligand’s investor materials and press coverage repeatedly include Jazz in the company’s alliance list, underscoring recurring partner acknowledgment (QuiverQuant investor release, 2026).
• Recordati S.p.A. (RCDTF) — Ligand’s FY2024 10‑K and market reports identify Recordati as Qarziba’s commercial licensee and a key royalty payor (FY2024 10‑K; OncoloyPipeline).
• Acrivon (ACRV) — OncologyPipeline lists ACR‑368 as a Phase‑2 program where Ligand has structured royalty economics (OncologyPipeline, 2024).
• Orchestra BioMed (OBIO) — TradingView coverage of Ligand’s SEC filings indicates Ligand invested in Orchestra BioMed cardiology programs and expects future royalties from that exposure (TradingView summary, FY2026).
• Castle Creek Biosciences — TradingView and GlobeNewswire note Ligand led a $75 million royalty financing for Castle Creek and entered into royalty financing tied to the D‑Fi Phase‑3 study (TradingView; GlobeNewswire, 2025–2026).
• Apeiron (APNC) — OncologyPipeline references Apeiron in connection with Qarziba and related royalty arrangements, illustrating Ligand’s multi‑party licensing structure for that asset (OncologyPipeline, 2024).
• Travere (FY2024 10‑K duplicate) — Ligand’s FY2024 10‑K explicitly enumerates Filspari royalties from Travere as a substantial portion of royalty revenue (FY2024 10‑K).

(If you want a downloadable, source‑linked spreadsheet of these relationships for modeling, visit https://nullexposure.com/.)

Risk, concentration and how to think about valuation

The revenue profile is driven by a small number of marketed drugs and multi‑year supply contracts (Captisol); that creates high leverage to partner sales execution and event‑driven volatility from milestones. The 10‑year Captisol supply agreement with Gilead reduces short‑term sales volatility for Captisol, but royalty concentration (Kyprolis, Filspari, Qarziba, etc.) leaves Ligand exposed if partner sales disappoint. These characteristics justify valuation models that emphasize scenario analysis for partner sales trajectories and discrete milestone timing.

For an investor brief with linked primary sources and a relationship table suitable for financial models, go to https://nullexposure.com/ — the homepage contains the full research and sourcing.

Final recommendation for due diligence

For investors and operators evaluating LGND exposure, prioritize (1) partner sales trends for Kyprolis, Filspari and Qarziba, (2) Captisol contract revenue cadence—particularly with Gilead, and (3) the timing and probability of milestone receipts from the many development‑stage assets Ligand finances. Each of these levers materially changes cash generation and valuation; review the cited FY2024 10‑K and the press releases above to reconcile company disclosures with market commentary. For deeper modeling support and source‑linked relationship files, visit https://nullexposure.com/.